{"title":"Potential drug interaction after withdrawal of nirmatrelvir-ritonavir in hospitalized patients with COVID-19 infection.","authors":"Yun Han, Yonglan Gou, Jieqiong Liu, Lingyan Yu, Yuhua Zhao, Zhenwei Yu","doi":"10.1016/j.jgar.2024.12.014","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Nirmatrelvir-ritonavir is effective in the treatment of SARS-CoV-2 infection. It can cause drug‒drug interactions (DDIs), even several days after withdrawal, due to irreversible inhibition of the cytochrome enzyme.</p><p><strong>Methods: </strong>Hospitalized patients diagnosed with COVID-19 infection and treated with nirmatrelvir-ritonavir were retrospectively included according to preset criteria. Personal information, as well as drug use, were obtained from the hospital information system. Potential DDIs were screened and classified according to three databases (FDA fact sheet, University of Liverpool Drug Interactions resources and Lexicomp).</p><p><strong>Results: </strong>A total of 332 hospitalized patients with COVID-19 infection who received nirmatrelvir-ritonavir treatment were included in this study. The prevalence of potential DDI risk after withdrawal of nirmatrelvir-ritonavir in hospitalized patients was 57.2%. Most patients resumed potentially interacting medications on the first day of nirmatrelvir-ritonavir withdrawal, and those drugs with DDI risk at the avoidance level mainly included dexamethasone and rivaroxaban, whereas drugs at the caution level mainly included lidocaine.</p><p><strong>Conclusion: </strong>The prevalence of potential DDI risk after withdrawal of nirmatlevir-ritonavir was high and should be given more attention.</p>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of global antimicrobial resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jgar.2024.12.014","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Nirmatrelvir-ritonavir is effective in the treatment of SARS-CoV-2 infection. It can cause drug‒drug interactions (DDIs), even several days after withdrawal, due to irreversible inhibition of the cytochrome enzyme.
Methods: Hospitalized patients diagnosed with COVID-19 infection and treated with nirmatrelvir-ritonavir were retrospectively included according to preset criteria. Personal information, as well as drug use, were obtained from the hospital information system. Potential DDIs were screened and classified according to three databases (FDA fact sheet, University of Liverpool Drug Interactions resources and Lexicomp).
Results: A total of 332 hospitalized patients with COVID-19 infection who received nirmatrelvir-ritonavir treatment were included in this study. The prevalence of potential DDI risk after withdrawal of nirmatrelvir-ritonavir in hospitalized patients was 57.2%. Most patients resumed potentially interacting medications on the first day of nirmatrelvir-ritonavir withdrawal, and those drugs with DDI risk at the avoidance level mainly included dexamethasone and rivaroxaban, whereas drugs at the caution level mainly included lidocaine.
Conclusion: The prevalence of potential DDI risk after withdrawal of nirmatlevir-ritonavir was high and should be given more attention.
期刊介绍：
The Journal of Global Antimicrobial Resistance (JGAR) is a quarterly online journal run by an international Editorial Board that focuses on the global spread of antibiotic-resistant microbes.
JGAR is a dedicated journal for all professionals working in research, health care, the environment and animal infection control, aiming to track the resistance threat worldwide and provides a single voice devoted to antimicrobial resistance (AMR).
Featuring peer-reviewed and up to date research articles, reviews, short notes and hot topics JGAR covers the key topics related to antibacterial, antiviral, antifungal and antiparasitic resistance.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
